Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies

Leukemia

Volumn 19, Issue 4, 2005, Pages 545-550

  Mühlemann, Kathrin ^a,b   Wenger, C ^a   Zenhausern R ^b   Tauber M G ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Aspergillosis; Fungal; Invasive infection; Neutropenic; Nosocomial

Indexed keywords

AMSACRINE; ANTIFUNGAL AGENT; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MELPHALAN; MITOXANTRONE;

ACUTE LEUKEMIA; ADULT; ARTICLE; ASPERGILLOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTEREMIA; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE DURATION; FEMALE; FEVER; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MYCOSIS; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

EID: 17144403463     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403674     Document Type: Article

References (23)

1. Bodey G, Bueltmann B, Duguid W, Gibbs D, Hanak H, Hotchi M et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Dis 1992; 11: 99-109.
2. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781-805.
3. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608-615.
4. von Eiff M, Roos N, Schulten R, Hesse M, Zuhlsdorf M, van de Loo J. Pulmonary aspergillosis: early diagnosis improves survival. Respiration 1995; 62: 341-347.
5. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 2000; 110: 273-284.
6. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: the major risk factor for invasive aspergillosis in patients with acute leukemia. Ann Int Med 1984; 100: 345-351.
7. Baddley JW, Stroud TP, Salzmann D, Pappas PG. Invasive mold infections in allogenic bone marrow transplant recipients. Clin Infect Dis 2001; 32: 1319-1324.
8. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 1993; 61: 4870-4877.
9. Ng TT, Robson GD, Denning DW. Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology 1994; 140: 2475-2479.
10. Bow EJ, Loewen R, Cheang MS, Schacter B. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis 1995; 21: 316-319.
11. Coiffier B, Frobert Y, Revol L. Polymorphonuclear function in acute myeloblastic leukemia. Biomedicine 1977; 27: 94-96.
12. Warnock DW, Hajjeh RA, Lasker BA. Epidemiology and prevention of invasive aspergillosis. Curr Infect Dis Rep 2001; 3: 507-516.
13. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
15. Denning DW, Marinus A, Cohen J, Spence D, Herbrecht R, Pagano L et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect 1998; 37: 173-180.
16. Lortholary O, Ascioglu S, Moreau P, Herbrecht R, Marinus A, Casassus P et al. Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: a European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the Intergroupe Francais du Myelome. Clin Infect Dis 2000; 30: 41-46.
17. Wiley JM, Smith N, Leventhal BG, Graham ML, Strauss LC, Hurwitz CA et al. Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: a multivariante analysis of risk factors. J Clin Oncol 1990; 8: 280-286.
18. Oren I, Haddad N, Finkelstein R, Rowe JM. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. Am J Hematol 2001; 66: 257-262.
19. Pagano L, Girmenia C, Mele L, Ricci P, Tosti ME, Nosari A, et al., GIMEMA Infection Program, Gruppo Italiano Malattie Ematologiche dell'Adulto. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica 2001; 86: 862-870.
20. Martino P, Raccah R, Gentile G, Venditti M, Girmenia C, Mandelli F. Aspergillus colonization of the nose and pulmonary aspergillosis in neutropenic patients: a retrospective study. Haematologica 1989; 74: 263-265.
21. Leenders AC, van Belkum A, Behrendt M, Luijendijk A, Verbrugh HA. Density and molecular epidemiology of aspergillus in air and relationship to outbreaks of aspergillus infection. J Clin Microbiol 1999; 37: 1752-1757.
22. de Repentigny L, Petitbois S, Boushira M, Michaliszyn E, Senechal S, Gendron N et al. Acquired immunity in experimental murine aspergillosis is mediated by macrophages. Infect Immun 1993; 6: 3791-3802.
23. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-917.